Investors / United States / Novalis LifeSciences
Novalis LifeSciences
Venture capital · Portsmouth, NH, United States · North America
Novalis LifeSciences is the direct investment vehicle of Novalis Capital Partners, a boutique investment and advisory firm for the life science industry founded in 2017. It manages venture capital and private equity funds totaling $500M in assets across three funds, while affiliated Novalis Advisory provides strategic advisory and investment banking services.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechdiagnosticslife science toolstherapeuticsprivate equity
Your fit with Novalis LifeSciences
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsNovalis LifeSciences lists 14 checked portfolio companies on its own site and is named in 1 funding round, 1 of them as lead. Its most frequent entry is Series B, 100% of the companies with a known first round. Its largest themes are Healthcare & Biotech (88%) and AI & Machine Learning (13%). 83% of its companies are based in United States. It invests most often alongside ARCH Venture Partners, Anterra Capital and DYDX Capital.
Counts come from funding rounds that name Novalis LifeSciences, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Novalis LifeSciences' whole history. Rounds on record name 1 company; its own site lists 14. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundNovalis LifeSciences does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 0% |
| Series B | 100% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 1 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 39th | 15 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 69th | 7% of companies confirmed by a round |
| Sector focus | 95th | 88% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| ARCH Venture Partners | 2 |
| Anterra Capital | 2 |
| DYDX Capital | 2 |
| iSelect Fund | 2 |
| +ND Capital | 1 |
| 8VC | 1 |
| Amadeus Capital Partners | 1 |
| Argonautic Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers14100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 88% | 15% |
| AI & Machine Learning | 13% | 18% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with ARCH Venture Partners
Compare Novalis LifeSciences head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Novalis LifeSciences| Date | Company | Stage |
|---|---|---|
| 3 Sept 2025 | Series B Led |
Round details for Novalis LifeSciences
Amounts, full round histories and every co-investor in Novalis LifeSciences' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
14 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Airna is developing novel medicines with the potential to deliver functional cures for patients using RNA editing technology. | Healthcare & Biotech | Portfolio page | ||
| Animol Discovery is accelerating the identification of innovative medicines for unmet needs in animals by using a unique approach to small molecule discovery and development. | Healthcare & Biotech | Portfolio page | ||
| BlueWhale Bio develops and provides cell-based therapies and related products, such as Synecta Activation and Expansion Solutions | Healthcare & Biotech | Portfolio page | ||
| Enko is an AI-informed crop health company that aims to change how the world grows by applying proven drug discovery and development approaches from the pharmaceutical industry to agriculture. | AI & Machine LearningAI & Machine Learning | Portfolio page | ||
| Etherna is a platform driven RNA-LNP technology company that partners with pharma and biotech organizations developing nucleic acid–based therapeutics | Healthcare & Biotech | Portfolio page | ||
| Flywheel provides a platform for managing medical imaging data and automating research workflows. | Healthcare & Biotech | Portfolio page | ||
| LevitasBio automates sample preparation for various biological samples using levitation technology | Healthcare & Biotech | Portfolio page | ||
| Mercy Bioanalytics develops blood-based tests to detect cancer at its earliest stages using extracellular vesicles and a proprietary platform | Healthcare & Biotech | Sept 2025Series B | Page + round | |
| Ori Biotech develops and provides a platform for cell and gene therapy manufacturing | Healthcare & Biotech | Portfolio page | ||
| Orogen Therapeutics is a drug discovery company utilizing proprietary, AI-enabled DNA encoded library technology to identify novel chemical matter against medically and commercially attractive drug targets. | Healthcare & Biotech | Portfolio page | ||
| Quanterix provides biomarker detection and spatial biology solutions | Healthcare & Biotech | Portfolio page | ||
| SkylineDx develops and offers molecular diagnostic tests to address unmet medical needs | Healthcare & Biotech | Portfolio page | ||
| Telesis Bio turns AI-designed sequences into ready-to-express DNA with intelligent, on-premises synthesis | Healthcare & Biotech | Portfolio page | ||
| Vigilant Biosciences develops advanced and accurate methods to aid in the early detection of oral cancer by identifying several unique biomarkers shown to be associated with oral cancer. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- novalislifesciences.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 3 Sept 2025
- Companies checked
- 14
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Novalis LifeSciences' profile as data
Pull Novalis LifeSciences' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/novalislifesciences.com
# also
GET /v1/firms/novalislifesciences.com/portfolio
GET /v1/firms/novalislifesciences.com/coinvestors
GET /v1/firms/novalislifesciences.com/news